Fulcrum Therapeutics is a clinical-stage biopharmaceutical company founded in 2016 that focuses on developing small molecule therapies for genetically defined diseases. The company uses its proprietary FulcrumSeek platform to identify drug targets that can modulate gene expression and protein production. Their lead programs target conditions like facioscapulohumeral muscular dystrophy (FSHD) and sickle cell disease. Fulcrum went public on NASDAQ in 2019 and continues to advance multiple candidates through clinical trials, representing a novel approach to treating genetic diseases through gene modulation rather than gene replacement.
Fulcrum Therapeutics has received investment from 1 venture capital firm.
Clinical-stage biopharmaceutical company developing small molecule drugs for genetically defined diseases using gene modulation approach.
Fulcrum Therapeutics has received investment from Atlas Venture. These venture capital firms and investors provide both capital and strategic support.
Fulcrum Therapeutics has raised $200M in total funding, with their most recent round being a IPO. The company operates in the Biotech sector.
Fulcrum Therapeutics was founded in 2016 and is headquartered in Cambridge, Massachusetts.
Fulcrum Therapeutics operates in the Biotech sector. Clinical-stage biopharmaceutical company developing small molecule drugs for genetically defined diseases using gene modulation approach.
